Ronald Carl Orlando

Athens, GA, United States of America

Ronald Carl Orlando


 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: Innovations by Ronald Carl Orlando

Introduction

Ronald Carl Orlando is a notable inventor based in Athens, GA (US), recognized for his contributions to the field of biopharmaceuticals. He holds a total of five patents, showcasing his innovative approach to biomolecular analysis and therapeutic drug development.

Latest Patents

Orlando's latest patents include "Radical dosimetry methods for in vivo hydroxyl radical protein foot-printing - Flash Photo-Oxidation Device" and "Higher Order Structural Analysis." These inventions focus on the higher order structural analysis of biomolecules, which is crucial for understanding how biomolecules interact within living systems. The analysis of biomolecular higher order structure (HOS) is essential, especially for biotherapeutics, as their therapeutic properties are closely linked to their HOS. Orlando's inventions provide new methodologies for determining biopharmaceutical HOS and associated conformations, addressing the growing demand for improved analytical techniques in the biopharmaceutical industry.

Career Highlights

Throughout his career, Orlando has worked with various companies, including Gennext Technologies, Inc. and Glycoscientific LLC. His work has significantly impacted the field of biopharmaceuticals, particularly in the development of analytical methods for biomolecular structures.

Collaborations

Orlando has collaborated with notable individuals in his field, including Scot Randy Weinberger and Joshua Shane Sharp. These collaborations have further enhanced his research and contributions to the industry.

Conclusion

Ronald Carl Orlando's innovative work in the analysis of biomolecular structures has made a significant impact on the biopharmaceutical industry. His patents and collaborations reflect his commitment to advancing the field and addressing the analytical needs of biotherapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…